- Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of $1.5 million
- Each unit consists of one common share and one share purchase warrant
- Proceeds from the offering will be used to pay current filing and regulatory fees, reduce debt, and begin production of ACP-01
- Hemostemix is an autologous stem cell therapy company
- Shares of Hemostemix Inc. (HEM) opened trading at C$0.35
Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of up to $1.5 million.
Each unit, priced at $0.30, consists of one common share and one share purchase warrant. Each warrant will entitle the holder to acquire one additional common share for $0.55 for 24 months.
Warrants are subject to an acceleration clause.
All securities issued will be subject to a four-month hold period.
Hemostemix is an autologous stem cell therapy company. The company has developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
Shares of Hemostemix Inc. (HEM) opened trading at C$0.35.
